New cream targets skin lymphoma without steroids
NCT ID NCT07658924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a cream called benvitimod (tapinarof) for people with cutaneous T-cell lymphoma, a rare skin cancer that causes red patches and itching. The cream is non-steroidal and works by targeting a specific receptor in skin cells. About 35 adults with the disease will apply the cream to one skin lesion and a placebo to another, allowing a direct comparison. Researchers will measure changes in lesion severity and itching over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Benvitimod (Tapinarof) cream
- What this could lead to
- If effective, this cream could offer a new, non-steroidal option to control skin lesions and itching in early-stage cutaneous T-cell lymphoma.
- What could go wrong
- This is a small, early-phase trial with only 35 participants. The cream may not work better than placebo, and side effects like skin irritation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A microchip implanted in tumors could reveal which drugs work best
- Skin gel targets immune signals in rare lymphoma
- Can a tailored exercise and diet plan beat cancer fatigue?
- Supercharged immune cells aim to stop lymphoma comeback
- Can a body wash improve skin bacteria in lymphoma patients?
- Scientists investigate skin microbiome in rare lymphoma